Please assess the completion status of the following clinical trial:

Trial Title: Phase III Efficacy and Safety Study of Oleogel-S10 in Epidermolysis Bullosa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients with the following subtypes of inherited EB: junctional EB (JEB), dystrophic EB (DEB), and Kindler EB aged ≥21 days~* Patients with an EB target wound (i.e., EB partial thickness wound of 10 cm² to 50 cm² in size aged ≥21 days and \<9 months)~* Patient and/or his/her legal representative has/have been informed, has/have read and understood the patient information/informed consent form, and has/have given written informed consent~* Patient and/or his/her legal representative must be able and willing to follow study procedures and instructions~Exclusion Criteria:~* Patient has EB simplex~* EB target wound that is ≥9 months old or has clinical signs of local infection~* Use of systemic antibiotics for wound-related infections within 7 days prior to enrolment~* Administration of systemic or topical steroids (except for inhaled, ophthalmic or topical applications, such as budesonide suspension for oesophageal strictures \[e.g., Pulmicort respules® 0.25 mg/2 mL or 0.5 mg/2 mL\]) within 30 days before enrolment~* Immunosuppressive therapy or cytotoxic chemotherapy within 60 days prior to enrolment~* Patient has undergone stem cell transplant or gene therapy for the treatment of inherited EB~* Current and/or former malignancy including basal cell carcinomas and squamous cell carcinomas~* Enrolment in any interventional study or treated with any investigational drug for any disease within 4 weeks prior to study entry~* Factors present in the patient and/or his/her legal representative that could interfere with study compliance such as inability to attend scheduled study visits or compliance with home dressing changes~* Pregnant or nursing women and women of childbearing potential including postmenarchal female adolescents not willing to use an effective form of birth control with failure rates \<1% per year (e.g., implant, injectable, combined oral contraceptive, intrauterine contraceptive device, sexual abstinence, vasectomised partner) during participation in the study (and at least 3 months thereafter)~* Patient is a member of the investigational team or his/her immediate family~* Patient lives in the same household as a study participant

- Gender: ALL
- Minimum Age: 21 Days
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Oleogel-S10 (Type: EXPERIMENTAL): None
- Control Gel (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).